Adele Nevot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Adele Nevot has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Abdessamad El Kaoutari
Aix Marseille Univ, CNRS, Inserm, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
15 shared publications - Audrey Francès
Team Therapeutic Innovation in Pancreatic Cancer, Centre de Recherches en Cancérologie de Toulouse, CRCT, Université de Toulouse, Inserm, CNRS, Toulouse, France
15 shared publications - Audrey Lumeau
Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK
15 shared publications - Charlene Lopez
Centre de Recherches en Cancerologie de Toulouse, CRCT, Universite de Toulouse, Inserm, CNRS, Toulouse, France
15 shared publications - Cyril Ribeyre
Institut de Génétique Humaine, CNRS, Université de Montpellier, Montpellier, France
15 shared publications - Emeline Sarot
Centre de Recherches en Cancerologie de Toulouse, CRCT, Universite de Toulouse, Inserm, CNRS, Toulouse, France
15 shared publications
Latest Publications
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S6 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S4 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S2 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S1 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S3 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- Open Access
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
- 1 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs
Figure S5 from Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs